https://www.biospace.com/calico-life-sciences-announces-first-participant-dosed-in-phase-1b-clinical-study-evaluating-abbv-cls-7262-for-the-treatment-of-vanishing-white-matter-disease
Calico Life Sciences Announces First Participant Dosed in Phase 1b Clinical Study Evaluating...
Apr 26, 2023 - Calico Life Sciences LLC today announced that the first participant has been dosed in a Phase 1b clinical trial, (study M23-523; NCT05757141), evaluating the...
calico life sciences